Inhaled insulin fails to get FDA approval; 2 additional studies were requested.
Bloomberg: MannKind Corp., the biotechnology company founded by billionaire inventor Alfred Mann, failed to win approval from U.S. regulators to market its first product, an inhaled insulin called Afrezza, for diabetes.